Full video transcriptClick to expand
Auto-generated transcript of @_priss97's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00Somebody
@_priss97's tirzepatide injection day celebration, fact-checked
Quick answer
Tirzepatide is a dual GLP-1/GIP receptor agonist that showed 22.5% weight loss in the SURMOUNT-1 trial at the 15mg dose. It's FDA-approved as Zepbound for chronic weight management in adults with obesity or overweight with comorbidities.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Tirzepatide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 6 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For @_priss97's tirzepatide injection day celebration, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Video claim decision path
Turn the claim into a safer next question
Direct answer
Compounded Tirzepatide should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.
Evidence check
Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.
Safety check
A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.
Next step
If the claim matches your goal, use the get-started flow to move from curiosity into a supervised prescription review.
Claim path
Keep researching this tirzepatide video claims cluster
Best for searchers deciding whether tirzepatide claims are stronger, safer, or more relevant than semaglutide claims.
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "@_priss97's tirzepatide injection day celebration, fact-checked" from PRISS • My Glowup Era 🤍. We read the clip as a GLP-1 social video fact-checks claim about Compounded Tirzepatide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Tirzepatide is a dual GLP-1/GIP receptor agonist that showed 22.
The reason this review is not generic is the source wording and the canonical claim label "glp1 it s timeeee my fav day of the week w join amble joi." In this clip, the useful excerpt is: "Somebody" That wording changes the review because it points to Compounded Tirzepatide safety, access, evidence, and fit, not a one-size-fits-all protocol.
The source trail for this page is checked against Tirzepatide Once Weekly for the Treatment of Obesity (2022), Continued Treatment With Tirzepatide for Maintenance of Weight Reduction (2024), and Tirzepatide for Obesity Treatment and Diabetes Prevention (2025), plus the creator's own wording. Compounded Tirzepatide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
Tirzepatide is a dual GLP-1/GIP receptor agonist that showed 22.
FormBlends verdict
Compounded Tirzepatide safety, access, evidence, and fit
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with the Compounded Tirzepatide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- Tirzepatide is a dual GLP-1/GIP receptor agonist that showed 22.5% weight loss in the SURMOUNT-1 trial at the 15mg dose. It's FDA-approved as Zepbound for chronic weight management in adults with obesity or overweight with comorbidities.
- Tirzepatide achieved 22.5% weight loss in SURMOUNT-1 trial at 15mg dose over 72 weeks
- 67% of trial participants experienced nausea, 30% had vomiting during treatment
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Tirzepatide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Tirzepatide guide, cost path, safety notes, and provider review before acting.
Review Compounded TirzepatideWhat You'll Learn
- Tirzepatide achieved 22.5% weight loss in SURMOUNT-1 trial at 15mg dose over 72 weeks
- 67% of trial participants experienced nausea, 30% had vomiting during treatment
- Zepbound costs approximately $1,060 monthly without insurance coverage
- FDA approval requires BMI ≥30 or ≥27 with weight-related health conditions
- Telehealth platforms can legally prescribe but must follow proper medical protocols
- Starting dose is 2.5mg weekly, gradually increased to minimize side effects
- Influencer marketing of prescription medications can create unrealistic expectations
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What does this video actually claim?
@_priss97 presents her "injection day" as her favorite day of the week, promoting tirzepatide (Zepbound) through telehealth platform Amble. She frames the weekly injection routine as something to celebrate.
The video doesn't make explicit medical claims but positions tirzepatide injections as a positive lifestyle choice. Her enthusiastic framing and hashtags like #glp1forweightloss suggest this is part of a weight management journey she's documenting for her audience.
The promotional nature is clear from her partnership with Amble, though she does properly disclose this relationship in her content.
Is tirzepatide actually effective for weight loss?
Yes, the clinical data for tirzepatide is genuinely impressive. The SURMOUNT-1 trial (Jastreboff et al., NEJM, 2022) showed 22.5% body weight reduction with the 15mg dose over 72 weeks.
That's substantially higher than what we see with semaglutide. The same trial found 15% weight loss with the 10mg dose and 20% with 15mg. About 40% of participants lost at least 25% of their body weight on the highest dose.
The FDA approved tirzepatide as Zepbound for weight management in November 2023, specifically for adults with obesity or overweight with weight-related health problems. So @_priss97 isn't wrong about the drug's potential.
What's problematic about this presentation?
Celebrating "injection day" as a favorite day glosses over real side effects many people experience. The SURMOUNT trials reported nausea in 67% of participants and vomiting in 30%.
Her upbeat framing might set unrealistic expectations for viewers considering tirzepatide. Most people don't love injection days, especially during the initial titration period when GI side effects peak.
The lifestyle influencer approach to prescription medications also raises questions. While she's transparent about her partnership, turning medical treatment into content can blur important boundaries between healthcare and social media marketing.
How does telehealth prescribing actually work?
Platforms like Amble can legally prescribe tirzepatide for weight management, but the process should involve proper medical screening. FDA guidelines require BMI of 30 or higher, or 27 with weight-related conditions.
Legitimate telehealth providers conduct medical histories, review contraindications, and provide ongoing monitoring. The starting dose is typically 2.5mg weekly, increasing gradually to minimize side effects.
However, the influencer marketing model does create pressure to make the process seem easier than it often is. Real medical care isn't always Instagram-worthy, and that's actually fine.
What should you know about tirzepatide costs and access?
Zepbound's list price is around $1,060 monthly without insurance. Many insurance plans don't cover it for weight loss, making telehealth platforms attractive for patients seeking access.
Some telehealth companies offer compounded versions at lower costs, though FDA guidance on compounding has been inconsistent. The supply shortages that plagued semaglutide are also affecting tirzepatide availability.
@_priss97's positive experience doesn't reflect the financial reality most people face. The celebratory tone might feel different when you're paying over $12,000 yearly out of pocket.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
PRISS • My Glowup Era 🤍 · TikTok creator
470.2K views on this video
It’s timeeee! My fav day of the week w/ @Join Amble ✨🧡 #joinamble #amble #ambleptnr #glp1forweightloss #glp1 #glp1community #weightlossmotivation #injectionday #tirzepatide #zepbound
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about tirzepatide achieved 22.5% weight loss in surmount-1 trial at 15mg?
Tirzepatide achieved 22.5% weight loss in SURMOUNT-1 trial at 15mg dose over 72 weeks
What does the video say about 67% of trial participants experienced nausea, 30% had vomiting during?
67% of trial participants experienced nausea, 30% had vomiting during treatment
What does the video say about zepbound costs approximately $1,060 monthly without insurance coverage?
Zepbound costs approximately $1,060 monthly without insurance coverage
What does the video say about fda approval requires bmi ≥30?
FDA approval requires BMI ≥30 or ≥27 with weight-related health conditions
What does the video say about telehealth platforms can legally prescribe?
Telehealth platforms can legally prescribe but must follow proper medical protocols
What does the video say about starting dose?
Starting dose is 2.5mg weekly, gradually increased to minimize side effects
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by PRISS • My Glowup Era 🤍, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.